From: APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling
APRIL Immunohistochemistry
Tumour Cell
Positive
130 (55.6%)
Weak
70 (29.9%)
Moderate
49 (20.9%)
Strong
11 (4.7%)
Stroma
Negative
104 (44.4%)
121 (51.7%)
113 (48.3%)